221 related articles for article (PubMed ID: 33880776)
1. Modified recombinant human IgG1-Fc is superior to natural intravenous immunoglobulin at inhibiting immune-mediated demyelination.
Baksmeier C; Blundell P; Steckel J; Schultz V; Gu Q; Da Silva Filipe A; Kohl A; Linnington C; Lu D; Dell A; Haslam S; Wang J; Czajkowsky D; Goebels N; Pleass RJ
Immunology; 2021 Sep; 164(1):90-105. PubMed ID: 33880776
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent inhibition of demyelination and microglia activation by IVIG.
Winter M; Baksmeier C; Steckel J; Barman S; Malviya M; Harrer-Kuster M; Hartung HP; Goebels N
Ann Clin Transl Neurol; 2016 Nov; 3(11):828-843. PubMed ID: 27844029
[TBL] [Abstract][Full Text] [Related]
3. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination.
Peschl P; Schanda K; Zeka B; Given K; Böhm D; Ruprecht K; Saiz A; Lutterotti A; Rostásy K; Höftberger R; Berger T; Macklin W; Lassmann H; Bradl M; Bennett JL; Reindl M
J Neuroinflammation; 2017 Oct; 14(1):208. PubMed ID: 29070051
[TBL] [Abstract][Full Text] [Related]
4. Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.
Thiruppathi M; Sheng JR; Li L; Prabhakar BS; Meriggioli MN
J Autoimmun; 2014 Aug; 52():64-73. PubMed ID: 24388113
[TBL] [Abstract][Full Text] [Related]
5. Live imaging of remyelination after antibody-mediated demyelination in an ex-vivo model for immune mediated CNS damage.
Harrer MD; von Büdingen HC; Stoppini L; Alliod C; Pouly S; Fischer K; Goebels N
Exp Neurol; 2009 Apr; 216(2):431-8. PubMed ID: 19320002
[TBL] [Abstract][Full Text] [Related]
6. Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination.
Liu Y; Given KS; Harlow DE; Matschulat AM; Macklin WB; Bennett JL; Owens GP
Acta Neuropathol Commun; 2017 Mar; 5(1):25. PubMed ID: 28340598
[TBL] [Abstract][Full Text] [Related]
7. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.
Anthony RM; Nimmerjahn F; Ashline DJ; Reinhold VN; Paulson JC; Ravetch JV
Science; 2008 Apr; 320(5874):373-6. PubMed ID: 18420934
[TBL] [Abstract][Full Text] [Related]
8. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures.
Pritchard AJ; Mir AK; Dev KK
PLoS One; 2014; 9(6):e99444. PubMed ID: 24911000
[TBL] [Abstract][Full Text] [Related]
10. IgG synthesis rate and anti-myelin oligodendrocyte glycoprotein antibody in CSF may be associated with the onset of CNS demyelination after haplo-HSCT.
Zhang XH; Zhao X; Wang CC; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Zhang YY; Mo XD; Chen Y; Wang Y; Fu HX; Chang YJ; Xu LP; Liu KY; Huang XJ
Ann Hematol; 2018 Aug; 97(8):1399-1406. PubMed ID: 29568992
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis).
Niknami M; Wang MX; Nguyen T; Pollard JD
J Peripher Nerv Syst; 2013 Jun; 18(2):141-52. PubMed ID: 23781961
[TBL] [Abstract][Full Text] [Related]
12. Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins ("IVIg").
Stangel M; Compston A; Scolding NJ
J Neuroimmunol; 2000 Mar; 103(2):195-201. PubMed ID: 10696915
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology.
Marta CB; Oliver AR; Sweet RA; Pfeiffer SE; Ruddle NH
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):13992-7. PubMed ID: 16172404
[TBL] [Abstract][Full Text] [Related]
14. The chemokine fractalkine (CX3CL1) attenuates H
O'Sullivan SA; Dev KK
J Neuroinflammation; 2017 Aug; 14(1):159. PubMed ID: 28810923
[TBL] [Abstract][Full Text] [Related]
15. Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.
Quast I; Keller CW; Weber P; Schneider C; von Gunten S; Lünemann JD
J Neuroinflammation; 2016 Feb; 13():42. PubMed ID: 26893156
[TBL] [Abstract][Full Text] [Related]
16. Myelin Oligodendrocyte Glycoprotein-IgG Contributes to Oligodendrocytopathy in the Presence of Complement, Distinct from Astrocytopathy Induced by AQP4-IgG.
Fang L; Kang X; Wang Z; Wang S; Wang J; Zhou Y; Chen C; Sun X; Yan Y; Kermode AG; Peng L; Qiu W
Neurosci Bull; 2019 Oct; 35(5):853-866. PubMed ID: 31041694
[TBL] [Abstract][Full Text] [Related]
17. Polymeric human Fc-fusion proteins with modified effector functions.
Mekhaiel DN; Czajkowsky DM; Andersen JT; Shi J; El-Faham M; Doenhoff M; McIntosh RS; Sandlie I; He J; Hu J; Shao Z; Pleass RJ
Sci Rep; 2011; 1():124. PubMed ID: 22355641
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.
Prabagar MG; Choi HJ; Park JY; Loh S; Kang YS
Clin Exp Med; 2014 Nov; 14(4):361-73. PubMed ID: 23996469
[TBL] [Abstract][Full Text] [Related]
19. [A patient with anti-myelin oligodendrocyte glycoprotein antibody-associated combined central and peripheral demyelination with anti-galactocerebroside and anti-GM1 antibodies].
Fuse K; Araki A; Morozumi S; Yasui K
Rinsho Shinkeigaku; 2023 Jul; 63(7):461-466. PubMed ID: 37394490
[TBL] [Abstract][Full Text] [Related]
20. IVIG in autoimmune disease - Potential next generation biologics.
Zuercher AW; Spirig R; Baz Morelli A; Käsermann F
Autoimmun Rev; 2016 Aug; 15(8):781-5. PubMed ID: 27019051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
